CHMP hilste de nye interimanalyser af data om effekt og sikkerhed for Rapinyl velkommen, men fandt, at de nye data skal anses for at være foreløbige data, da de samlede forsøgsresultater endnu ikke er tilgængelige for en vurdering.
The CHMP welcomed the new interim analyses of efficacy and safety data for Rapinyl, but considered that the new data must be regarded as preliminary data, as the complete trial results are not yet available for assessment.